Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment
Authors
Keywords
-
Journal
MOLECULAR PSYCHIATRY
Volume 20, Issue 10, Pages 1179-1187
Publisher
Springer Nature
Online
2015-06-09
DOI
10.1038/mp.2015.74
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lessons from a Failed γ-Secretase Alzheimer Trial
- (2014) Bart De Strooper CELL
- γ-Secretase inhibitors and modulators
- (2013) Todd E. Golde et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice
- (2013) Sandra Sivilia et al. BMC NEUROSCIENCE
- γ-Secretase Modulator (GSM) Photoaffinity Probes Reveal Distinct Allosteric Binding Sites on Presenilin
- (2013) Nikolay Pozdnyakov et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects
- (2013) Yanke Yu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Longitudinal Amyloid Imaging in Mouse Brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 Mouse Models of Alzheimer Disease
- (2013) A. Snellman et al. JOURNAL OF NUCLEAR MEDICINE
- Longitudinal Assessment of Cerebral -Amyloid Deposition in Mice Overexpressing Swedish Mutant -Amyloid Precursor Protein Using 18F-Florbetaben PET
- (2013) A. Rominger et al. JOURNAL OF NUCLEAR MEDICINE
- Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures
- (2013) S Liebscher et al. MOLECULAR PSYCHIATRY
- Semagacestat's fall: where next for AD therapies?
- (2013) NATURE MEDICINE
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
- (2013) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
- (2012) Vladimir Coric et al. ARCHIVES OF NEUROLOGY
- Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice
- (2012) Ana María Martín-Moreno et al. Journal of Neuroinflammation
- Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
- (2012) Kathryn Rogers et al. Molecular Neurodegeneration
- Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease
- (2012) André Manook et al. PLoS One
- Presenilin Is the Molecular Target of Acidic γ-Secretase Modulators in Living Cells
- (2012) Thorsten Jumpertz et al. PLoS One
- Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease
- (2011) B Van Broeck et al. BRITISH JOURNAL OF PHARMACOLOGY
- Rivastigmine Transdermal Patch
- (2011) Sohita Dhillon DRUGS
- Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1
- (2011) Yu Ohki et al. EMBO JOURNAL
- Memantine in dementia: a review of the current evidence
- (2011) Nathan Herrmann et al. EXPERT OPINION ON PHARMACOTHERAPY
- Novel γ-Secretase Enzyme Modulators Directly Target Presenilin Protein
- (2011) Amelie Ebke et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Attenuated Aβ42Responses to Low Potency γ-Secretase Modulators Can Be Overcome for Many Pathogenic Presenilin Mutants by Second-generation Compounds
- (2011) Benedikt Kretner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression
- (2011) Stefan J. Teipel et al. PROGRESS IN NEUROBIOLOGY
- Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure
- (2010) Stefanie Hahn et al. JOURNAL OF NEUROCHEMISTRY
- Modulation of γ-Secretase Reduces β-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease
- (2010) Maria Z. Kounnas et al. NEURON
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial
- (2009) Robert C. Green JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- -Secretase Inhibition Reduces Spine Density In Vivo via an Amyloid Precursor Protein-Dependent Pathway
- (2009) T. Bittner et al. JOURNAL OF NEUROSCIENCE
- Worldwide variation in the doubling time of Alzheimer's disease incidence rates
- (2008) Kathryn Ziegler-Graham et al. Alzheimers & Dementia
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
- (2008) Adam S. Fleisher et al. ARCHIVES OF NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started